UNITY Biotech's lead compound lags behind the Regeneron’s eye drug
Biospace - 27-May-2023UBX1325 showed disappointing results in phase II macular degeneration trial - further analysis is required
Join the club for FREE to access the whole archive and other member benefits.
Multiplatform Journalist and Content Specialist
Ana Mulero has been reporting on pharma and biotech for nearly 10 years. Ana has held editorial and reporting positions at the Washington Business Journal, Industry Dive, FDA News, the Regulatory Affairs Professional Society and BioCentury. Previously, she worked at the Washington Business Journal, FierceHealthcare and The Hill Rag, among other publications. Her work has also appeared in Endpoints News, Xtelligent, BioWorld, HealthLeaders, among other publications.
Ana completed Bachelor’s of Arts in Communication with a Minor in Italian at Arizona State University. She earned her Master’s in Multiplatform Journalism from the University of Maryland, and is currently pursuing her second Master’s degree of MBA in Healthcare Management at the Florida Institute of Technology.
Visit website: https://www.biospace.com/staticpages/10284/contributors/#AnaMulero
See alsoDetails last updated 03-Jul-2023
UBX1325 showed disappointing results in phase II macular degeneration trial - further analysis is required